PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, recently announced preliminary revenues for fourth-quarter 2023. The robust preliminary results drove up the company’s shares by 0.1% in the pre-market trading session.The company is expected to release fourth-quarter results in February.Per the preliminary report, fourth-quarter 2023 total revenues are estimated to be $58.4 million, up 113% year over year. The Zacks Consensus Estimate of $54.1 million lies below the preliminary fig ...